In this module you will learn the impact of progressive chronic kidney disease (CKD) on fracture incidence and morbidity.
ATTENTION! Kindly note that if you were in attendance of the live webinar you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record the 1 CPD point from the live webinar, invalidating any additional CPD points from the report.
0 of 5 questions completed
You have already completed the module before. Hence you can not start it again.
Module is loading…
You have to finish following quiz, to start this quiz:
Time has elapsed
Thank you, we will review your submission and notify you of your results via email.
If not received within 5 hours due to spam, don’t worry, it will show in your profile.
1. Which statement is incorrect? With regard to hip fracture in renal patients:
2. FRAX predicts fracture probability in all CKD stages, but it is unknown whether CKD requires adjustments to conventional FRAX estimates and, if so, to what extent.
3. In terms of the trajectory of biochemical bone derangement that accompanies progression of CKD, which option is correct?
4. Which range of PTH concentration is associated with normal bone turnover in the CKD patient?
5. Which option is correct? Osteoporosis drugs that have been proven to preserve bone density and reduce fracture risk in CKD 1-4/5 are: